Lv31
370 积分 2023-08-01 加入
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
4天前
已完结
POS0017 Bispecific T Cell-Engaging Antibodies to Target TRBV9+ Autoreactive T Cells in Axial Spondyloarthritis
7天前
已关闭
POS0017 Bispecific T Cell-Engaging Antibodies to Target TRBV9+ Autoreactive T Cells in Axial Spondyloarthritis
7天前
已关闭
T-cell-engaging bispecific antibodies in cancer
2个月前
已完结
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
5个月前
已完结
Optimization of Drug-Linker to Enable Long-term Storage of Antibody–Drug Conjugate for Subcutaneous Dosing
6个月前
已完结
Endometrial Cancer
7个月前
已完结
Endometrial cancer
7个月前
已完结
Clinical significance of B7-H4 expression in ovarian cancer: a meta-analysis ofproportions and time-to-event survival outcomes
7个月前
已完结
BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy
8个月前
已完结
皖公网安备34019202002308
